Michael B Ward (Michael Ward)

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 6

Top Topics

Stem Cell Transplantation

Hydrogen Peroxide

Chronic Obstructive Pulmonary Disease

Top Venues

British journal of clinical pharmacology

Journal of clinical pharmacy and therapeutics

Respiratory research

This page only lists publications with an associated author ORCID identifier.

Publications

Jack Luke Janetzki, Nicole L Pratt, Michael B Ward, Matthew J Sykes
Application of an Integrative Drug Safety Model for Detection of Adverse Drug Events Associated With Inhibition of Glutathione Peroxidase 1 in Chronic Obstructive Pulmonary Disease. Pharmaceutical research (2023)
Jack Luke Janetzki, Matthew J Sykes, Michael B Ward, Nicole L Pratt
Chronic Obstructive Pulmonary Disease Adverse Event Signals Associated with Potential Inhibitors of Glutathione Peroxidase 1: A Sequence Symmetry Analysis. Drug safety (2023)
Thu-Lan Kelly, Michael B Ward, Nicole L Pratt, Emmae Ramsay, Marianne H Gillam, Elizabeth Ellen Roughead
The association between exacerbation of chronic obstructive pulmonary disease and timing of paracetamol use: a cohort study in elderly Australians. Respiratory research 23 (1) (2022)
Jack Luke Janetzki, Matthew J Sykes, Michael B Ward, Nicole L Pratt
Proton pump inhibitors may contribute to progression or development of chronic obstructive pulmonary disease-A sequence symmetry analysis approach. Journal of clinical pharmacy and therapeutics 46 (6) (2021)
Stephanie E Reuter, Hayley B Schultz, Michael B Ward, Crystal L Grant, Gemma M Paech, Siobhan Banks, Allan M Evans
The effect of high-dose, short-term caffeine intake on the renal clearance of calcium, sodium and creatinine in healthy adults. British journal of clinical pharmacology 87 (11) (2021)
Courtney De Vries, Svetla Gadzhanova, Matthew J Sykes, Michael B Ward, Elizabeth Ellen Roughead
A Systematic Review and Meta-Analysis Considering the Risk for Congenital Heart Defects of Antidepressant Classes and Individual Antidepressants. Drug safety 44 (3) (2020)